TRAIL expression up-regulated by interferon-γ via phosphorylation of STAT1 induces myeloma cell death

Anticancer Research

Volumn 26, Issue 6 B, 2006, Pages 4115-4124

  Miura, Yoshie ^a   Tsujioka, Takayuki ^a   Nishimura, Yasumitsu ^a   Sakaguchi, Haruko ^a   Maeda, Megumi ^a   Hayashi, Hiroaki ^a   Dong, Maolong ^a   Hyodoh, Fuminori ^a   Yata, Ken Ichiro ^a   Wada, Hideho ^a   Sugihara, Takashi ^a   Otsuki, Takemi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

IFN ; Myeloma; STAT1; TRAIL

Indexed keywords

GAMMA INTERFERON; JANUS KINASE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CELL DEATH; CELL VIABILITY; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MUTATION; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON TYPE II; MULTIPLE MYELOMA; PHOSPHORYLATION; STAT1 TRANSCRIPTION FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TYRPHOSTINS; UP-REGULATION;

EID: 33845945377     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Guikema JE, Hovenga S, Vellenga E and Bos NA: Heterogeneity in the multiple myeloma tumor clone. Leuk Lymphoma 45: 857-871, 2004.
2. Devenney B and Erickson C: Multiple myeloma: an overview. Clin J Oncol Nurs 8: 401-405, 2004.
3. Hideshima T, Bergsagel PL, Kuehl WM and Anderson KC: Advances in biology of multiple myeloma: clinical applications. Blood 104: 607-618, 2004.
4. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R and Crowley J: Treatment of multiple myeloma. Blood 103: 20-32, 2004.
5. Kishimoto T: Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol 23: 1-21, 2005.
6. Trikha M, Corringham R, Klein B and Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665, 2003.
7. Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Otsuyama K, Zheng X and Kawano MM: Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation. Leuk Lymphoma 44: 1477-1481, 2003.
8. Lauta VM: A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97: 2440-2452, 2003.
9. Klein B and Bataille R: Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 6: 273-284, 1992.
10. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J and Rossi JF: Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78: 106-113, 2003.
11. Schaar CG, Kluin-Nelemans HC, Te Marvelde C, le Cessie S, Breed WP, Fibbe WE, van Deijk WA, Fickers MM, Roozendaal KJ, Wijermans PW and Dutch-Belgian Hemato-Oncology Cooperative Group HOVON: Interferon-α as maintenance therapy in patients with multiple myeloma. Ann Oncol 16: 634-639, 2005.
12. Lundin J, Osterborg A, Bjorkholm M, Bjorkstrand B, Celsing F, Hjalmar V, Linder O, Luthman M, Merup M, Tidefelt U, Mellstedt H and Myeloma Group of Central Sweden: Phase II study of cyclophosphamide, interferon-α and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III. Hematol J 4: 248-252, 2003.
13. Myeloma Trialists' Collaborative Group: Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113: 1020-1034, 2001.
14. Zervas K, Pouli A, Gregoraki B, Anagnostopoulos N, Dimopoulos MA, Bourantas K, Tzilianos M, Barbarousi D, Venetis E, Vyniou N and Maniatis A: Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-α (IFN-α) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group. Eur J Haematol 66: 18-23, 2001.
15. Oancea M, Mani A, Hussein MA and Almasan A: Apoptosis of multiple myeloma. Int J Hematol 80: 224-231, 2004.
16. Crowder C, Dahle O, Davis RE, Gabrielsen OS and Rudikoff S: PML mediates IFN-α-induced apoptosis in myeloma by regulating TRAIL induction. Blood 105: 1280-1287, 2005.
17. Minami R, Muta K, Ilseung C, Abe Y, Nishimura J and Nawata H: Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-α. Exp Hematol 28: 244-255, 2000.
18. Otsuki T, Yamada O, Sakaguchi H, Tomokuni A, Wada H, Yawata Y and Ueki A: Human myeloma cell apoptosis induced by interferon-α. Br J Haematol 103: 518-529, 1998.
19. Egle A, Villunger A, Kos M, Bock G, Gruber J, Auer B and Greil R: Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-α2. Eur J Immunol 26:3119-3126, 1996.
20. Caraglia M, Vitale G, Marra M, Budillon A, Tagliaferri P and Abbruzzese A: a-interferon and its effects on signalling pathways within cells. Curr Protein Pept Sci 5: 475-485, 2004.
21. Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA and Abbruzzese A: α-interferon and its effects on signal transduction pathways. J Cell Physiol 202: 323-335, 2005.
22. Panaretakis T, Pokrovskaja K, Shoshan MC and Grander D: Interferon-α-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene 22: 4543-4556, 2003.
23. Jourdan M, De Vos J, Mechti N and Klein B: Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-α and insulin-like growth factor 1. Cell Death Differ 7: 1244-1252, 2000.
24. Puthier D, Thabard W, Rapp M, Etrillard M, Harousseau J, Bataille R and Amiot M: Interferon a extends the survival of human myeloma cells through an up-regulation of the Mcl-1 anti-apoptotic molecule. Br J Haematol 112: 358-363, 2001.
25. Shiratsuchi M, Muta K, Umemura T, Nishimura J, Nawata H and Kozuru M: Telomerase activity in myeloma cells is closely related to cell cycle status, but not to apoptotic signals induced by interferon-α. Leuk Lymphoma 34: 349-359, 1999.
26. Liu P, Oken M and Van Ness B: Interferon-α protects myeloma cell lines from dexamethasone-induced apoptosis. Leukemia 13: 473-480, 1999.
27. Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF and Klein B: IFN-α is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. J Immunol 161: 2692-2699, 1998.
28. Palumbo A, Bruno B, Boccadoro M and Pileri A: Interferon-γ in multiple myeloma. Leuk Lymphoma 18: 215-219, 1995.
29. Portier M, Zhang XG, Caron E, Lu ZY, Bataille R and Klein B: γ-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and down-regulation of IL-6-receptor expression in vitro. Blood 81: 3076-3082, 1993.
30. Jernberg-Wiklund H, Pettersson M and Nilsson K: Recombinant interferon-γ inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. Eur J Haematol 46: 231-239, 1991.
31. Palumbo A, Battaglio S, Napoli P, Omede P, Fusaro A, Bruno B, Boccadoro M and Pileri A: Recombinant interferon-γ inhibits the in vitro proliferation of human myeloma cells. Br J Haematol 86: 726-732, 1994.
32. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL and Anderson KC: Interleukin-6 overcomes p21WAF1 up-regulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 90: 279-289, 1997.
33. Spets H, Georgii-Hemming P, Siljason J, Nilsson K and Jernberg-Wiklund H: Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-γ and interferon-γ in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood 92: 2914-2923, 1998.
34. Faggioli L, Merola M, Hiscott J, Furia A, Monese R, Tovey M and Palmieri M: Molecular mechanisms regulating induction of interleukin-6 gene transcription by interferon-γ. Eur J Immunol 127: 3022-3030, 1997.
35. Dimberg LY, Dimberg AI, Ivarsson K, Stromberg T, Osterborg A, Nilsson K, Oberg F and Wiklund HJ: Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood 106: 1346-1354, 2005.
36. Otsuki T, Yata K, Takata-Tomokuni A, Hyodoh F, Miura Y, Sakaguchi H, Hatayama T, Hatada S, Tsujioka T, Sato Y, Murakami H, Sadahira Y and Sugihara T: Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. Br J Haematol 127: 292-298, 2004.
37. Otsuki T, Sakaguchi H, Hatayama T, Wu P, Takata A and Hyodoh F: Effects of all-trans retinoic acid (ATRA) on human myeloma cells. Leuk Lymphoma 44: 1651-1656, 2003.
38. Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisue H, Yata K, Uno M, Yawata Y and Ueki A: Estrogen receptors in human myeloma cells. Cancer Res 60: 1434-1441, 2000.
39. Otsuki T, Hata H, Harada N, Matsuzaki H, Yata K, Wada H. Yawata Y, Ueki A and Yamada O: Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient. Int J Hematol 72: 216-222, 2000.
40. Westendorf JJ, Lammert JM and Jelinek DF: Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 85: 3566-3576, 1995.
41. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H and Ritz J: Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 17: 51-61, 1995.
42. Liu Q, El-Deiry WS and Gazitt Y: Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Exp Hematol 29: 962-970, 2001.
43. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T and Anderson KC: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98: 795-804, 2001.
44. Gazitt Y: TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13: 1817-1824, 1999.
45. Wang Q, Ji Y, Wang X and Evers BM: Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 276: 466-471, 2000.